Abstract
It is estimated that by 2030 nearly three-quarters of persons living with HIV will be 50 years and older. The aging HIV population presents a new clinical concern for HIV providers: adverse effects from polypharmacy. An aging population means more comorbidities and potentially more drug-drug interactions for providers to manage. This review discusses major comorbidities including cardiovascular disease, anticoagulation, hypertension, diabetes mellitus and malignancy and considerations for drug-interactions with antiretrovirals.
Original language | English (US) |
---|---|
Pages (from-to) | S173-S184 |
Journal | AIDS |
Volume | 31 |
DOIs | |
State | Published - Jun 1 2017 |
Keywords
- aging
- antiretroviral therapy
- drug interactions
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases